Lilly-backed Oyster Therapeutics raises $60m for neurological degraders
London-based life science venture capital fund 4BIO Capital led the investment. New participants in the round included Actium Group, CE Ventures, Eli Lilly, and TOHO Ventures, managed by
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.